Skip to main content
Submitted by Dr S. Patel on 9 July 2018

You may have heard people refer to a ‘metastatic cancer' or  say that ‘cancer has metastasized’ or is ‘in Stage 4’. But what does that really mean. Dr. Shital Raval explains. 

What is Metastasis?

Metastasis is a term for when cancer has spread to a different part of a body from where it first originated. Because metastatic cancer is more difficult to control and treat, it is categorized as the last stage or Stage IV.

How does Metastasis happen?

This happens when cancer cells break away from the original tumour and enter the circulatory (blood stream) or lymphatic system. These cells can settle in and start growing at the new spot. 
Certain cancers such as those of the blood like leukemia and lymphoma are already spread through the body and hence not stated to as metastatic.

In some cases, cancer cells may fall or grow into adjoining organs, this is called seeding. It is seen mostly in certain abdominal cancers of the appendix or the ovaries. Here the cancer cells tend to break off and grow along the lining of the abdomen or pelvis.

Cancer cells often travel via the lymphatic system which connects the lymph nodes throughout the body via a fluid called lymph. Cancers often spread to the local lymph nodes (nodes located closest to the primary tumor). If a tumor is found in two or more 2 lymph nodes, it is categorized as Stage 3 Cancer. 

Almost all cancers have the ability to metastasize and whether they do depends on:

  • the type of cancer
  • how fast it is growing
  • size and location of the cancer
  • duration of the cancer
  • if the cancer was treated 
  • how well the treatments worked

Where do cancers usually metastasize?

The most common parts of the body for the cancer to spread are vital organs such as bones, brain, liver, lymph nodes and lungs. Pleural spaces (linings) around the lungs and abdominal cavity are also common. Seldom, tumors also spread to the muscles, skin and other organs of the body. Here is a list of common cancers and where they usually spread.

Type of Cancer Sites of Metastasis

Lung Cancer

Brain, bone, liver, adrenal glands

Breast Cancer

Bones, liver, lungs, chest wall, brain

Prostate Cancer

Bones

Colorectal Cancer

Liver, lungs

Endometrium/Ovarian Cancer

Liver, lung, abdominal & pelvic organs, Lining of the abdomen & pelvis

How is metastasis detected?

Often times, symptoms of the metastatic tumor may be the first ones to occur. For example in pancreatic cancer, when metastasis reaches the liver, symptoms of jaundice, dark urine etc. emerge. That’s when pancreatic cancer may be discovered. In others, bone pain when investigated may reveal metastasis to the bone. This is why we often have late detection and poor prognosis of cancers, when the disease has well advanced. 

It is imperative that patients who have early stage cancer do routine follow-up with their doctors to check for signs of metastasis. Besides tumor markers, imaging tests such as PET, MRI and CT scans are used to detect metastatic cells. 

How is metastatic cancer treated?

Treatment always depends on the type of cancer and hence biopsy is done to identify the tumor by looking at the cells under a microscope. Since a metastatic tumor has originated elsewhere, it will contain the cells of the primary tumor. It means that if a breast cancer has metastasized to the brain, the tumor in the brain is made of breast cancer cells and not brain cancer cells. This is important for the right course of treatment to be done.

Treatment for late stage or advanced metastases is palliative and aims to prolong and improve quality of life for the patient. Treatment can slow down the progress of the cancer and provide supportive therapies besides the conventional ones like Chemotherapy, Radiation, Surgery and Immunotherapy.

Reference Resources:

American Society of Clinical Oncology (ASCO), www.cancer.net
Patient resource, https://www.patientresource.com/Metastatic_Disease.aspx
Canadian Cancer Society, www.cancer.ca

Community
Condition

Stories

  • Novel Immunotherapy Vaccine Decreases Recurrence in HER2 Breast Cancer Patients
    Women with breast cancer tumors that overexpress human epidermal growth factor receptor 2 (HER2) may benefit from a novel vaccine to prevent recurrence A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression…
  • My cancer doesn't define who I am
    "I was originally diagnosed with locally advanced cancer, so that means it's advanced within in the chest. Mine was triple negative. It's the most aggressive form of cancer," she said. Her breast cancer diagnosis came in 2008. She found out about her metastatic breast cancer in January 2011, at 33 years old. "Two and half years after my original diagnosis, I found another lump," she said as she held back tears. "It varies from person to person. But my experience has been a bit of a roller…
  • Joan Lunden talks about her Breast Cancer
    How she shared the information with her kids and why - http://www.today.com/health/joan-lunden-how-i-told-my-kids-i-have-cancer-2D80186889 The choices she made in terms of treatment - http://www.people.com/article/joan-lunden-chemotherapy-cancer
  • Breast cancer drug Perjeta appears to extend patients lives
    According to reports from clinical trials, Roche’s breast cancer drug Perjeta displays “unprecedented” life-extending effects, helping patients live an average of 15.7 months longer than they would on chemotherapy and an older drug. 15.7 months is a significant amount of time for metastatic breast cancer patients, who are, on average, given two to three years to live after their diagnosis. Perjeta, then, has the capacity to increase that time by 50 to 75 percent.  http://www…
  • Heal Your Cancer
    Don’t fight cancer, heal it by attending to body, mind and spirit, says surgical oncologist Dr Vishal Rao. A child developing from an embryo in a mother’s womb is, in reality, a set of rapidly multiplying cells. But they are controlled and regulated. So, we choose to ‘love’ those cells. But when another set of cells multiply rapidly within our body, albeit haphazardly, we call it ‘Cancerous’! These cells are not foreign cells that have made an appearance from outside,…
  • “I was open to anything, just trying to find things to help me stay alive,” said Geoffrey Boycott
    Geoffrey Boycott describes how counting off his radiotherapy sessions like runs in cricket and Feng Shui helped him survive cancer http://www.telegraph.co.uk/sport/cricket/11080199/Geoffrey-Boycott-reve…
  • Mayo Clinic partners with IBM to match Cancer Patients with Clinical Trials
    Mayo Clinic unveiled today a partnership with IBM to harness the power of its Watson supercomputer to match patients with the right clinical trials. Starting early next year, Watson will initially enroll patients with breast, colorectal and lung cancers based on eligibility. There are 170,000 ongoing clinical trials around the world, however, according to the Center for Information and Study on Clinical Research Participation, only 6% are completed on time. Enrolling patients in the…
  • FDA approves first use of novel immune system drug for cancer
    This new class of drugs unleashes the body's immune system to fight tumors. This seems to solve a century-old mystery of how cancerous cells manage to evade the body's immune system. The drug which Merck will sell under the name of Keytruda was approved by patients with advanced melanoma who have exhausted other therapies.  http://www.nytimes.com/2014/09/05/business/merck-wins-approval-of-novel-immune-system-drug-for-cancer.html?emc=eta1
  • Breast cancer specialist reports advance in treatment of triple-negative breast cancer that disproportionately affects younger women
    We hope that this means fewer women will relapse and die of their cancer, though the study is not large enough to prove this conclusively. Of the two agents we studied, we are more encouraged by the results from the addition of carboplatin, since it was associated with fewer and less concerning additional side effects than bevacizumab," Sikov explains.  William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's…
  • Do more for depressed cancer patients
    Clinical depression was much more prevalent among cancer patients than in the general population, where around 2% of people suffer from the mental illness at any point in time. Among cancer patients, clinical depression ranged from 13% in people with lung cancer to 6% in people with genitourinary cancer. The study's lead author Michael Sharpe, from Oxford University, said: "Major depression is really quite common in people with cancer and the perhaps surprising finding is that most of it goes…